FDA OKs Tofacitinib (Xeljanz) for Active Psoriatic Arthritis

The JAK inhibitor is indicated for patients who have failed to respond adequately or are intolerant to methotrexate or other disease-modifying antirheumatic drugs.
FDA Approvals

http://ift.tt/2B9NiKv